Liver transplant selection criteria and outcomes in critically ill patients with ACLF.

Acute-on-Chronic Liver Failure Intensive Care Unit Liver Cirrhosis Liver transplantation Multiple Organ Failure Prognosis Waiting List

Journal

JHEP reports : innovation in hepatology
ISSN: 2589-5559
Titre abrégé: JHEP Rep
Pays: Netherlands
ID NLM: 101761237

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 25 04 2023
revised: 30 08 2023
accepted: 13 09 2023
medline: 11 12 2023
pubmed: 11 12 2023
entrez: 11 12 2023
Statut: epublish

Résumé

Retrospective studies have reported good results with liver transplantation (LTx) for acute-on-chronic liver failure (ACLF) in selected patients. The aim of this study was to evaluate the selection process for LTx in patients with ACLF admitted to the intensive care unit (ICU) and to assess outcomes. This prospective, non-interventional, single high-volume center study collected data on patients with ACLF admitted to the ICU between 2017-2020. Among 200 patients (mean age: 55.0 ± 11.2 years and 74% male), 96 patients (48%) were considered potential candidates for LTx. Unfavourable addictology criteria (n = 76) was the main reason for LTx ineligibility. Overall, 69 patients were listed for LTx (34.5%) and 50 were transplanted (25% of the whole population). The 1-year survival in the LTx group was significantly higher than in the non-transplanted group (94% This prospective analysis of outcomes of patients with ACLF admitted to the ICU highlights the drastic nature of selection in this setting. Unfavourable addictology criteria, mechanical ventilation and increasing number of organ failures since admission were predictive of absence of LTx, futility and death. Liver transplantation (LT) is the best therapeutic option in selected cirrhotic patients admitted to the ICU with acute on chronic liver failure. However, the selection criteria are poorly described and based on retrospective studies. This is the first prospective study that aimed to describe the selection process for LT in a transplant center. Patients with ACLF should be admitted to the ICU and evaluated within a short period of time for LT. In the context of organ shortage, eligibility for LT and either absence of LT, futility of care or death are better clarified in our study. These are mainly determined by prolonged respiratory failure and worsening of organ failures since ICU admission. Considering worldwide variations in the etiology and definition of ACLF, transplant availability and a narrow therapeutic window for transplant further prospective studies are awaited.

Sections du résumé

Background & Aims UNASSIGNED
Retrospective studies have reported good results with liver transplantation (LTx) for acute-on-chronic liver failure (ACLF) in selected patients. The aim of this study was to evaluate the selection process for LTx in patients with ACLF admitted to the intensive care unit (ICU) and to assess outcomes.
Methods UNASSIGNED
This prospective, non-interventional, single high-volume center study collected data on patients with ACLF admitted to the ICU between 2017-2020.
Results UNASSIGNED
Among 200 patients (mean age: 55.0 ± 11.2 years and 74% male), 96 patients (48%) were considered potential candidates for LTx. Unfavourable addictology criteria (n = 76) was the main reason for LTx ineligibility. Overall, 69 patients were listed for LTx (34.5%) and 50 were transplanted (25% of the whole population). The 1-year survival in the LTx group was significantly higher than in the non-transplanted group (94%
Conclusion UNASSIGNED
This prospective analysis of outcomes of patients with ACLF admitted to the ICU highlights the drastic nature of selection in this setting. Unfavourable addictology criteria, mechanical ventilation and increasing number of organ failures since admission were predictive of absence of LTx, futility and death.
Impact and implications UNASSIGNED
Liver transplantation (LT) is the best therapeutic option in selected cirrhotic patients admitted to the ICU with acute on chronic liver failure. However, the selection criteria are poorly described and based on retrospective studies. This is the first prospective study that aimed to describe the selection process for LT in a transplant center. Patients with ACLF should be admitted to the ICU and evaluated within a short period of time for LT. In the context of organ shortage, eligibility for LT and either absence of LT, futility of care or death are better clarified in our study. These are mainly determined by prolonged respiratory failure and worsening of organ failures since ICU admission. Considering worldwide variations in the etiology and definition of ACLF, transplant availability and a narrow therapeutic window for transplant further prospective studies are awaited.

Identifiants

pubmed: 38074503
doi: 10.1016/j.jhepr.2023.100929
pii: S2589-5559(23)00260-4
pmc: PMC10703599
doi:

Types de publication

Journal Article

Langues

eng

Pagination

100929

Informations de copyright

© 2023 The Author(s).

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in relation to this study. Please refer to the accompanying ICMJE disclosure forms for further details.

Références

Hepatology. 2020 Sep;72(3):1109-1116
pubmed: 32416642
J Gastroenterol Hepatol. 2021 Jan;36(1):240-248
pubmed: 32478437
Transplantation. 2021 Mar 1;105(3):561-568
pubmed: 32568955
J Hepatol. 2021 Sep;75(3):610-622
pubmed: 33951535
Crit Care Med. 2014 Jul;42(7):1666-75
pubmed: 24732239
Ann Gastroenterol. 2014;27(2):113-120
pubmed: 24733601
J Intensive Care. 2017 Aug 3;5:51
pubmed: 28794881
J Hepatol. 2018 Oct;69(4):803-809
pubmed: 29730473
J Hepatol. 2014 Mar;60(3):570-8
pubmed: 24280294
Liver Transpl. 2010 Feb;16(2):222-8
pubmed: 20104499
Gastroenterology. 2013 Jun;144(7):1426-37, 1437.e1-9
pubmed: 23474284
Liver Int. 2017 May;37(5):684-693
pubmed: 28052486
N Engl J Med. 2011 Nov 10;365(19):1790-800
pubmed: 22070476
N Engl J Med. 2020 May 28;382(22):2137-2145
pubmed: 32459924
J Hepatol. 2021 May;74(5):1097-1108
pubmed: 33227350
Crit Care. 2013 Feb 09;17(1):R28
pubmed: 23394270
Gastroenterology. 2019 Apr;156(5):1381-1391.e3
pubmed: 30576643
Liver Transpl. 2020 Jul;26(7):906-915
pubmed: 32365422
PLoS One. 2013 Sep 02;8(9):e72893
pubmed: 24023787
Ann Intensive Care. 2017 Dec;7(1):33
pubmed: 28321803
Gastroenterology. 2012 Oct;143(4):986-94.e3; quiz e14-5
pubmed: 22750200
Liver Transpl. 2022 Jan;28(1):17-26
pubmed: 34431204
Liver Transpl. 2020 Dec;26(12):1594-1602
pubmed: 32574423
Am J Transplant. 2020 Sep;20(9):2437-2448
pubmed: 32185866
J Hepatol. 2020 Apr;72(4):688-701
pubmed: 31778751
J Hepatol. 2017 Oct;67(4):708-715
pubmed: 28645736
J Hepatol. 2020 Mar;72(3):481-488
pubmed: 31669304
J Hepatol. 2017 Dec;67(6):1185-1193
pubmed: 28802877
J Hepatol. 2021 Mar;74(3):670-685
pubmed: 33301825

Auteurs

Sophie-Caroline- Sacleux (SC)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Philippe Ichaï (P)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Audrey Coilly (A)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Marc Boudon (M)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Elise Lemaitre (E)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Rodolphe Sobesky (R)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Eleonora De Martin (E)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Valérie Cailliez (V)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Ilias Kounis (I)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Edoardo Poli (E)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Marie-Amélie Ordan (MA)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Alina Pascale (A)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Jean-Charles Duclos-Vallée (JC)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Cyrille Feray (C)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Daniel Azoulay (D)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Eric Vibert (E)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Daniel Cherqui (D)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

René Adam (R)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Didier Samuel (D)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Faouzi Saliba (F)

AP-HP, Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif, France.
University Paris Saclay, France.
INSERM Unit N°1193, Villejuif, France.

Classifications MeSH